John L. Allinson, FIBMS, Director, Veeda Clinical Research Ltd.

Charles Benson, M.D., Ph.D., Medical Advisor, Exploratory & Program Medicine, Eli Lilly & Co.

Graham Betton, Ph.D., Senior Principal Scientist, Safety Assessment, AstraZeneca Pharmaceuticals

Viswanath Devanarayan, Ph.D., Director, Statistics, Biomarker Research, Abbott Laboratories

Mark Fidock, Ph.D., Associate Research Fellow, Biomarkers and Translational Biology, Pfizer Global Research and Development 

Chris Harbron, Technical Lead Statistician, Discovery Statistics, AstraZeneca Pharmaceuticals

William Hempel, Ph.D., Scientific Director Biology, BioSystems International

Jochen Kuhlmann, M.D., Consultant, Global Clinical Pharmacology, Bayer Healthcare AG

Michael Lahn, Ph.D., Medical Advisor, Lilly Deutschland GmbH

Vincenzo Libri, M.D., Ph.D., Head, Translational Clinical Science, Clinical Pharmacology & Discovery Medicine, Neurology and Gastro-Intestinal Centre of Excellence in Drug Discovery, GlaxoSmithKline

Ruth E. March, Ph.D., Senior Principal Scientist, R&D Genetics, AstraZeneca Pharmaceuticals

Amin Rostami-Hodjegan, Ph.D., Reader in Clinical Pharmacokinetics & Drug Metabolism, Academic Unit of Clinical Pharmacology, School of Medicine, University of Sheffield

Stefan Scherer, M.D., Ph.D., Biomarker Program Leader, AVASTIN, F. Hoffmann-La Roche Ltd. 

David E. Slavin, M.D., Ph.D., Head, Business Innovations Unit, Pfizer Global Research and Development

Joachim Stangier, Ph.D., Senior Principal Scientist, Drug Metabolism & Pharmacokinetics, Boehringer Ingelheim Pharma GmbH & Co. KG

Alain J. van Gool, Ph.D., Director, Genomics & Proteomics; Chair, Biomarker Platform, N.V. Organon

Karthik Venkatakrishnan, Ph.D., Associate Director, Clinical Pharmacology, Pfizer Global Research and Development

Georg Wensing, Ph.D., Head, Pharmacodynamics, Clinical Pharmacology, Global Drug Discovery, Bayer HealthCare AG

Hans Winkler, Ph.D., Senior Director, Functional Genomics, Johnson and Johnson 
Pharmaceutical R&D